Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer - Takeaways - MDSpire

Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer

  • By

  • Hang Li

  • Qian Li

  • Xiaojing Tie

  • Feng Ji

  • LiNa Ma

  • Chunyan Ma

  • May 28, 2026

  • 0 min

Share

  • 1

    The study evaluated serum levels of miR-21, VEGF, and CA15-3 for breast cancer diagnosis among 106 women with breast cancer.

  • 2

    Serum miR-21 levels were significantly higher in breast cancer patients compared to healthy controls and those with benign nodules.

  • 3

    ROC curve analysis showed miR-21 had an AUC of 0.897 for distinguishing breast cancer from healthy individuals.

  • 4

    MiR-21 demonstrated superior sensitivity and specificity compared to traditional biomarkers VEGF and CA15-3 in breast cancer diagnosis.

  • 5

    The study highlights miR-21 as a promising non-invasive biomarker for early breast cancer detection, though further validation is needed.

Original Source(s)

Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer

  • by Hang Li, Qian Li, Xiaojing Tie, Feng Ji, LiNa Ma, Chunyan Ma

  • May 28, 2026

Related Content

MIT president: Why so many optimistic scientists are losing heart

25HC regulates the polarization of CD163+ macrophages in the immune microenvironment of triple-negative breast cancer through the interferon pathway

Combined reconstruction of complex chest wall defects using mesh-supported rigid materials and abdominal flap strategies: a retrospective clinical study